Skip to main content
Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
33.79
-0.71 (-2.06%)
Nov 13, 2026, 4:00 PM EST - Market closed

Castle Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
377.13344.23332.07219.79137.0494.09
Revenue Growth
9.78%3.66%51.09%60.38%45.65%50.18%
Gross Profit
290.66273.2271.86174.81105.0378.26
Operating Income
-28.04-22.718.67-67.98-91.14-40.08
Net Income
-23.01-24.1618.25-57.47-67.14-31.29
Earnings Per Share
-0.77-0.830.62-2.14-2.58-1.24
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
277.67299.51293.13243.1258.63329.63
Total Debt
36.5737.0226.4515.4113.558.31
Net Cash (Debt)
241.09262.49266.69227.69245.08321.33
Net Cash Growth
-3.72%-1.57%17.13%-7.09%-23.73%-21.60%
Net Cash Per Share
8.069.069.128.509.4112.78

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
39.7464.3564.87-5.63-41.66-18.98
Capital Expenditures
-35.78-36.02-28.33-13.62-5.63-3.48
Free Cash Flow
3.9628.3336.54-19.25-47.29-22.47
Free Cash Flow Growth
-84.38%-22.48%----

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
77.07%79.37%81.87%79.53%76.64%83.18%
Operating Margin
-7.43%-6.60%2.61%-30.93%-66.51%-42.60%
Pretax Margin
-6.00%-8.57%6.49%-26.10%-50.28%-42.53%
Profit Margin
-6.10%-7.02%5.49%-26.15%-48.99%-33.26%
FCF Margin
1.05%8.23%11.00%-8.76%-34.51%-23.88%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--40.91---
P/FCF Ratio
262.7740.0920.43---
PS Ratio
2.763.302.252.644.5311.72